Explore the Agenda
7:30 am Check-In & Coffee
8:30 am Chair’s Opening Remarks
8:40 am Industry Leader’s Fireside Chat: Evaluating the Global Treg Landscape to Explore the Future of Space
- Exploring the global Treg landscape to identify emerging opportunities and the direction of future Treg development
- Exploring the interest in Treg collaboration and investment amid industry changes and recent changes in the industry
- Discussing the broad landscape of Treg therapy economics considering cost, reimbursement and tariff impacts
9:30 am Keynote Presentation: Uncovering Clinical Advances with thyTregs™ to Expand the Frontiers of Treg Therapy
- Unveiling clinical data on Thytech’s thyTregs™ therapy preventing transplant rejection in heart transplant children
- Exploring thymic-derived allogeneic Treg therapeutic potential across multiple
- indications including Chron’s disease
- Discussing the escalation capacity of thyTregs™ to accelerate therapeutic success
10:00 am Reserved for Harvard Medical School
10:30 am Morning Break & Speed Networking
As the community unites, this session will provide valuable networking time with your peers, enabling you to forge new and lasting connections.
Discover Treg Innovations to Transform Transplant Clinical Success
11:30 am Delve into Functional Insights from Quell’s Treg Therapy to Advance Liver Transplant Outcomes
- Discover how Quell’s therapy controls immune responses to protect donor liver function
- Gain translational insights from liver biopsy data demonstrating therapeutic impact
- Understand how additional immune responses can be integrated to enhance transplant success
- Exploring allogenic therapies and rheumatoid treatments in the future of Quell Therapeutics
12:00 pm Utilizing Tregs to Minimize Immunosuppression Following Transplants
- Explore how Treg therapies can minimize reliance on broad immunosuppressive drugs, reducing side effects
- Review clinical and translational data supporting Treg use to improve transplant outcomes and long-term graft survival
12:30 pm Development of a Novel Normothermic Machine Perfusion-Based Approach for Treg Cell Therapy in Organ Transplantation
- Objective & Innovation: Introducing a novel strategy using normothermic machine perfusion (NMP) as a platform for organ-directed delivery of Treg cells prior to transplantation
- Methodology: Developing proprietary reagents for rapid activation of Treg cells and perfusate enhancement to preserve Treg functionality and support liver metabolic stability during the NMP procedure
- Key Findings: Successful procedural efficacy (Treg infiltration) and organ (liver) functional integrity after NMP/Treg treatment
- Clinical Implications: Establishing a new therapeutic niche for organ-specific cellular immunotherapy prior to transplantation, with the potential to reduce reliance on long term systemic immunosuppression
1:00 pm Lunch Break & Networking
Navigating Evolving FDA & GMP Standards to Accelerate Scalable & Compliant Treg Therapeutics
2:00 pm Reserved for genOway
2:30 pm Panel Discussion: Evaluating Changing FDA & GMP Expectations to Overcome Regulatory Challenges & Accelerate Clinical Approval
- Understand how Treg GMP and approval processes have evolved for 2026
- Sharing FDA interactions to reveal and combat manufacturing and regulatory approval challenges
- Identifying opportunities for accelerated regulatory progression amid regulatory changes
3:15 pm Afternoon Break & Poster Session
This is your opportunity to contribute to the conversation and share your cutting-edge research with this community while discovering exciting work carried out by your peers. To submit a poster, please contact [email protected].
Exploring Translational & Regulatory Insights to Advance Next-Gen Chronic Autoimmune Disease Therapies
4:00 pm Expanding Treatment Possibilities with GentiBio’s Autologous & Allogenic Therapeutic Development
• Exploring early clinical insights and data from GNTI-122 combatting T1D
• Uncovering GentiBio’s shielding technology to refine allogenic therapies
• Translating allogenic technology into Treg products
4:30 pm CoRe-T: The CD6/CTLA4 CAR-Treg. A First-in-class T-cell Targeting and Treg Specific Signalling Treg Therapy
- Introduction to CoRe-T (Counter Regulatory) CAR-Tregs: The CD6/CTLA-4 CAR-Treg
- Overview of Clinical Data in Chronic Refractory GvHD patients
- Shaping the future of targeted Treg therapies with multi-edited allogenic CAR-Tregs.
- Updates on PolTREG’s clinical pipeline and EMA’s agreement to receive submission of a Marketing Authorization for PTG-007 + Rituximab in Stage 3 T1D